Congressional Letter to Administration on Importance of Animal Biotechnology
October 8, 2021
As you know, several challenges facing the agriculture industry and our communities have emerged or intensified in recent years. Zoonotic disease, climate change, and a growing global population require us to consider new solutions to protect our food supply and sustainably meet demand. Ongoing research and existing innovations in animal genetics show great promise in addressing these challenges. However, an efficient, risk and science-based regulatory system that can create a safe, predictable path to market is imperative to capitalizing on these solutions. We believe the existing U.S. regulatory process for the review of animals developed or improved through biotechnology requires significant improvement to meet that standard, and we encourage the U.S. Department of Agriculture (USDA) and Food & Drug Administration (FDA) to continue working with each other and with other relevant federal partners to appropriately modernize this important process.
Download Full Comments Below
Congressional Letter to Administration on Importance of Animal Biotech
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
BIO submitted these comments in response to the United States Patent and Trademark Office’s May 10, 2024, Notice of Proposed Rulemaking regarding Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting.
As you know, several challenges facing the agriculture industry and our communities have emerged or intensified in recent years. Zoonotic disease, climate change, and a growing global population require us to consider new solutions to protect our food supply and sustainably meet demand. Ongoing research and existing innovations in animal genetics show great promise in addressing these challenges. However, an efficient, risk and science-based regulatory system that can create a safe, predictable path to market is imperative to capitalizing on these solutions. We believe the existing U.S. regulatory process for the review of animals developed or improved through biotechnology requires significant improvement to meet that standard, and we encourage the U.S. Department of Agriculture (USDA) and Food & Drug Administration (FDA) to continue working with each other and with other relevant federal partners to appropriately modernize this important process.